← Back to 2C-T-4

2C-T-4 Stats & Data

Psychedelic Research-chemical

T-4 2ct4 2c-t4 2-ct4 2ct-4

PubChem CID 44350070

PubChem

MW255.38

FormulaC13H21NO2S

LogP2.5

IUPAC2-(2,5-dimethoxy-4-propan-2-ylsulfanylphenyl)ethanamine

SMILESCC(C)SC1=C(C=C(C(=C1)OC)CCN)OC

InChIKeyHDYZSVKZKDPLDT-UHFFFAOYSA-N

Chemical Class 2C-x phenethylamine

Psychoactive Class Psychedelic

Half-Life Unknown in humans; effect duration suggests a multi‑hour active window but pharmacokinetics have not been formally characterized.

Receptor Profile

Receptor Actions

Agonists

5-HT2A receptor agonist (partial)

5-HT2B receptor agonist

5-HT2C receptor agonist

History & Culture

2C-T-4 was first documented in the scientific literature by Alexander Shulgin and his colleagues in a 1991 journal article. Later that same year, Shulgin provided a more comprehensive account of the compound in his book PiHKAL (Phenethylamines I Have Known and Loved), where he devoted a chapter to describing his personal experiences with the substance. In these writings, Shulgin reported an intense "plus-four" experience on his rating scale at a dose of 12 milligrams, representing the highest possible classification for subjective psychedelic effects. The abbreviated name "T-4" has occasionally been used to refer to 2C-T-4, though this terminology carries potential for confusion. The same designation is shared by cyclotrimethylenetrinitramine (RDX), a powerful explosive, as well as thyroxine, a naturally occurring amino acid hormone in the body. Shulgin himself noted this naming overlap in his writings, clarifying that the psychedelic compound shares nothing beyond the shorthand with either of these unrelated substances.

Effect Profile

Curated + 10 Reports

Psychedelic 7.0

Strong visuals with moderate auditory effects and body load, mild headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Based on reports from:

PiHKAL PiHKAL #41: 2C-T-4 Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 2C-T-4

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Oral

30 minutes - 2.0 hours

1-2 hours

3-6 hours

4-6 hours

4-8 hours

Total: 10-18 hours

Insufflated

4-19 minutes

30 minutes - 1.0 hours

3-6 hours

4-6 hours

4-8 hours

Total: 10-18 hours

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown in humans; effect duration suggests a multi‑hour active window but pharmacokinetics have not been formally characterized.

Addiction Potential

Very low. No evidence of physical dependence; psychological habituation possible with frequent use, similar to other classical psychedelics.

Tolerance Decay

Full tolerance 1d Half tolerance 7d Baseline ~14d

Model extrapolated from serotonergic psychedelic tolerance patterns; individual variability high; data are largely anecdotal for 2C‑T‑4 specifically.

Cross-Tolerances

LSD

Psilocybin

Other 2C phenethylamines

Experience Report Analysis

Erowid

20 Reports

10 Single-substance

2003–2022 Date Range

5 With Age Data

14 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 10 experience reports (10 single-substance Erowid)

10 Reports

14 Effects Detected

8 Positive

3 Adverse

3 Neutral

Effect Sentiment Distribution

Confidence Distribution

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 10 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Positive Effects 8

Visual Distortions 10 of 10 70%

Color Enhancement 6 of 10 70%

Music Enhancement 5 of 10 70%

Empathy 5 of 10 70%

Stimulation 5 of 10 70%

Closed-Eye Visuals 4 of 10 70%

Introspection 3 of 10 70%

Euphoria 3 of 10 70%

Adverse Effects 3

Nausea 5 of 10 70%

Anxiety 3 of 10 70%

Pupil Dilation 3 of 10 70%

Dosage Distribution

Dose distribution from experience reports, one dose per report (the first listed). Values above Q3 + 3×IQR are left out as outliers.

Median: 15.0 mg IQR: 10.0–15.0 mg n=12 2 outliers left out

Real-World Dose Distribution

62K Doses

From 31 individual dose entries. Values above Q3 + 3×IQR are left out as outliers.

Oral (n=29)

Median: 15.0mg 25th: 8.0mg 75th: 18.0mg 90th: 22.0mg

Common Combinations

Most co-occurring substances, as a share of all 20 reports filed under 2C-T-4; whiskers are 95% intervals

Form / Preparation

Most common forms and preparations, as a share of the 15 reports that give one

Too few reports for bars: these forms come from 15 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Powder / Crystals 8 of 15
Capsule 4 of 15
Pill / Tablet 2 of 15

Body-Weight Dosing

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Values above Q3 + 3×IQR are left out as outliers.

Median: 0.189 mg/kg IQR: 0.178–0.268 mg/kg n=13

Redose Patterns

Redosing behavior across 16 reports

3 of 16 Redosed

1.3 Avg Doses

60m Median Interval

Too few reports for a chart: redosing is known from 16 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

Single dose 13 of 16
Redosed 3 of 16

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Canada	Schedule III (CDSA)	Designated as a controlled substance under Schedule III of the Controlled Drugs and Substances Act effective October 31, 2016. Possession, trafficking, and production carry criminal penalties.
China	Controlled substance	Added to the national list of controlled substances in October 2015. Manufacturing, distribution, and possession are prohibited.
Denmark	Schedule B	Listed as a Schedule B controlled substance under Danish drug control legislation. This classification restricts possession and distribution.
Sweden	Prohibited (health hazard)	Classified as a health hazard by the Swedish National Institute of Public Health (Statens folkhälsoinstitut) on July 15, 2007 under regulation SFS 2007:600. Controlled under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor), making both sale and possession illegal.
United States	Schedule I	Designated as a Schedule I controlled substance on July 9, 2012 under the Synthetic Drug Abuse Prevention Act of 2012. Classified as having high abuse potential with no currently accepted medical use in treatment.

Harm Reduction

drugs.wiki

• Identity and isomer check: historic market confusion between 2C‑T‑4 and the inactive isomer psi‑2C‑T‑4 existed due to a gamma/psi transcription error in early online PiHKAL copies; ensure proper labeling and avoid vendors using “gamma‑2C‑T‑4.”

• Reagent tests: Marquis typically shifts orange→salmon/red with 2C‑T‑4, similar to other 2C‑T compounds; reagent colors cannot distinguish 2C‑T‑2/‑4/‑7, so laboratory verification is recommended.

• Come‑up can be slow/uneven; avoid redosing for at least 3 hours. Related thio‑phenethylamines (e.g., 2C‑T‑7) frequently take 1–3 h to fully develop orally.

• Insufflation significantly increases adverse effects with this family and has been implicated in multiple 2C‑T‑7 fatalities; oral administration is the lower‑risk route.

• Expect moderate body load (nausea, muscle tension, vasoconstriction) and difficulty sleeping; plan a next‑day recovery window and avoid late‑evening dosing.

• Tolerance builds acutely after one session and typically halves over ~7 days, with cross‑tolerance to other serotonergic psychedelics (LSD, psilocybin, 2C‑x).

• Avoid combinations with lithium, MAOIs, tramadol, or strong stimulants. Cannabis can unpredictably intensify effects.

• Market adulteration/misrepresentation: materials sold as “2C” or “tusi/pink cocaine” often contain mixed stimulants, ketamine, MDxx, or trace opioids rather than true 2C compounds; use trusted lab checking services when possible.

• Use a 0.001 g (1 mg) scale; the dose‑response becomes steep beyond ~15 mg in many users, and inter‑individual variability is high.

• Eat lightly 3–4 h prior and sip fluids; antiemetics like ondansetron (non‑sedating, non‑serotonergic) have been used anecdotally for nausea but avoid serotonergic agents.